Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Relationship between obesity and the sense of taste is complex, with many inconsistent and conflicting findings that are largely methodology dependent.

The impact of glucagon-like peptide-1 analogues on taste remains largely unaddressed.

Who Took Part

According to the abstract, 30 women were involved.

By PubMed's age tags, the people studied were young adults and adults, women only.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Only one side, usually the women, was kept unaware of whether Semaglutide was given.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

Change in taste recognition was assessed by 16 strips impregnated with 4 different concentrations of the 4 basic tastes.

Tongue biopsies were performed for gene expression analysis.

Brain responses to visual cues of sweet and savory foods and to sweet solution dripping on the tongue were evaluated by functional magnetic resonance imaging.

What Was Measured

The subject headings attached to it are Obesity, Polycystic Ovary Syndrome, Glucagon-Like Peptides, Taste, Magnetic Resonance Imaging, Tongue and Brain.

Author keywords: fMRI, semaglutide, taste recognition and tongue biopsy.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Semaglutide in 30 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Semaglutide compound page, all human trials.